Navigation Links
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
Date:2/8/2013

SEOUL, South Korea, Feb. 8, 2013 /PRNewswire/ -- RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III assessing the company's RNL-Astrostem™ stem cell drug in patients with cerebral palsy. The purpose of this study is to assess conclusive efficacy of stem cells for the treatment of cerebral palsy in 45 subjects over 11 months.  The study is to be conducted through Kyung Hee University Hospital at Gangdong and THE Bethesda Hospital.

RNL-Astrostem™, has already completed a phase I trial to assure safety, including tests to rule out toxicity or tumorigenicity.  This trial was conducted at the Seoul National University's Clinical Research Institute.  In addition, the phase I study has confirmed the safety of stem cells infused by IV, as published in a leading peer-reviewed journal, Stem Cells and Development ("Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans," February 2011). In the course of successful safety trials, scientists found significant evidence suggesting the potential for efficacy of stem cells in treatment of cerebral palsy. In addition, a case report with obvious result of improvement was published in another internationally renowned journal. RNL BIO believes that with successful trials and approval of the KFDA, it will be possible to commercialize RNL-Astrostem™ by 2014, revolutionizing the possibility to cure this incurable disease of children, which can only be managed with current technologies.

Cerebral Palsy is caused by non-progressive brain damage from single or multiple defect(s) on the nerve/muscular system and results in disorder in motion and sensory integration. According to Health Insurance Review and Assessment Service, the prevalence of cerebral palsy is 3.5 pe
'/>"/>

SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
2. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
3. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
6. Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  The board of directors of VirtualScopics, Inc. ... clinical trial imaging solutions, today announced that James ... effective immediately.  Mr. Groff has held the role of ... VirtualScopics in January 2006 as an accounting manager and ... "When the board of VirtualScopics asked Jim to assume ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan ... to its Board of Directors, enhancing executive oversight ... company, a leading licensed producer of medicinal cannabis ... has 13 years, experience in producing and supplying ... including Canada. As previously announced ...
(Date:8/21/2014)... 2014  Cyberonics, Inc. (NASDAQ: CYBX ) today ... Quarterly highlights 1   Operating results ... first quarter of fiscal 2014, and other achievements, include: ... of 6.8%; , Strong international net sales of $13.2 ... , U.S. net product sales reached a new high ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16
... 20, 2010 ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... Beaumont Hospitals, world renowned heart center has expanded and ... the new Ernst Cardiovascular Center at Beaumont Hospital, Royal ... Cardiovascular Center offer breakthrough surgeries and treatments for people ... also the new home for Beaumont,s innovative "7 tests ...
Cached Medicine Technology:Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 2Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 3Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 4Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 5Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 6Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 7Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 8Beaumont Hospital Opens New Ernst Cardiovascular Center 2
(Date:8/21/2014)... 21, 2014 The costs paid by consumers ... rise, according to insurer data. The Quotes Pros company is ... time using its tools at http://quotespros.com . , ... homepage connects with providers offering multiple coverage packages for dental ... to the public are now easier to compare using the ...
(Date:8/21/2014)... Today, Zane Benefits, the #1 Online Health ... credits in 2015. , According to Zane Benefits, premium ... Affordable Care Act (ACA), premium tax credits are available ... through the Health Insurance Marketplaces. , The new article ... of the tax credits, updated for 2015. , ...
(Date:8/21/2014)... Calcium buildup in the coronary arteries of chronic kidney ... disease risk, according to a new study in the ... ( JASN ). Researchers at the Johns Hopkins Bloomberg ... two other commonly used measures of subclinical atherosclerosis in ... kidney disease. , Approximately 50 percent of all patients ...
(Date:8/21/2014)... University of Texas MD Anderson Cancer Center today announced ... specialized breast screening at a network of community breast ... in late November, MD Anderson will become the exclusive ... Memorial Hermann,s 10 breast care centers, located in Memorial ... Over time, the network will expand to Memorial Hermann,s ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Not only is eating ... save them hundreds of health-care dollars a year, a new ... professor of public health sciences at Wake Forest Baptist Medical ... and obese type 2 diabetes patients. Participants ... assigned to either an intensive "lifestyle change program" focused on ...
Breaking Medicine News(10 mins):Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2
... Sciton introduces ProLipo,PLUS(TM), an FDA-cleared, minimally invasive, ... fat, resulting in collagen remodeling and,tissue tightening. ... wavelengths in,one laser for optimal body sculpting results. ... it can also be utilized as a standalone ...
... FOR CAREER OF SCIENTIFIC DISCOVERY IN MOLECULAR IMAGING , ... The Radiologic Society of North America (RSNA) honored Ralph Weissleder, ... recognition afforded annually to one scientist who has made original ... of research. Dr. Weissleder is Professor at Harvard Medical ...
... to qualified recipients , , ... honor 31 recipients of the 2008 UCB Family Epilepsy Scholarship(TM) at ... American Epilepsy Society Annual Meeting. The scholarship is awarded to ... seek personal growth through higher learning. , , ...
... Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical company, announced ... is scheduled to,participate at the RBC Capital Markets 2008 ... "Delivering Novel Drug Solutions: The Future of Drug,Delivery." ... December,11, 2008 at 1:30 PM Eastern Time. , ...
... Americans cut prescription costs without compromising drug safety , ... A collection of online educational materials are now ... the dangers of contaminated or counterfeit drugs. Unveiled ... is designed to help consumers ensure the safety of ...
... and Alternative Risk Transfer Capabilities Further Expand Company,s Specialty Offerings- , ... Partner Agents- , , WORCESTER, Mass., ... THG ), a leading super regional property and casualty company, announced ... Holdings, Inc. , , (Logo: ...
Cached Medicine News:Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 3Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 2Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 3Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 4Health News:Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel 2Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 2Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 3Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 4Health News:The Hanover Insurance Group Completes Acquisition of AIX Holdings, Inc. 2Health News:The Hanover Insurance Group Completes Acquisition of AIX Holdings, Inc. 3
Its MicroPoint design and reference marks at 10, 50 and 100 L ensure accurate performance with a variety of multi-channel and single-channel pipettors....
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
For plaque coring...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: